NCT03113188View on ClinicalTrials.gov

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

CBP501

CBP501, CDDP plus Nivolumab

Trial Locations (3)

70121

Ochsner Clinic Foundation, New Orleans

85258

HonorHealth, Scottsdale

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

CanBas Co. Ltd.

INDUSTRY

NCT03113188 - CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors | Biotech Hunter | Biotech Hunter